community acquired bacterial pneumonia cabp epidemiology forecast

Overview

DelveInsight’s Community-Acquired Bacterial Pneumonia (CABP) - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the community-acquired bacterial pneumonia, historical and forecasted epidemiology as well as the community-acquired bacterial pneumonia trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan. 

Community-Acquired Bacterial Pneumonia Disease Understanding

Community-acquired Bacterial Pneumonia is a common, acute, severe infection of the lung parenchyma. It is a major cause of mortality in adults. It is one of the most frequent respiratory illnesses among various infections triggering sepsis. The Global Burden of Disease Study identified lower respiratory tract infection (LRTI) as the second most common cause of death and years of life lost. Microbiologically, bacteria are common agents in pneumonia, with Streptococcus pneumoniae being the most common cause worldwide. 

Streptococcus pneumoniae is a bacteria most often responsible for Community-acquired pneumonia in adults worldwide. Some other common bacteria that cause community-acquired pneumonia are Haemophilus influenza and Mycoplasma pneumoniae. Pneumonia caused by chlamydia and mycoplasma is often clinically indistinguishable from other pneumonia.

Symptoms of community-acquired bacterial pneumonia include malaise, chills, rigor, fever, cough, dyspnea, and chest pain. Cough typically is productive in older children and adults and dry in infants, young children, and older adults. Dyspnea usually is mild and exertional and is rarely present at rest. Chest pain is pleuritic and is adjacent to the infected area.

Community-Acquired Bacterial Pneumonia (CABP) Diagnosis 

Although the diagnostic criteria for community-acquired pneumonia/community-acquired bacterial pneumonia seem relatively straightforward, making the correct diagnosis can be difficult. A thoughtful history and physical examination with close attention to the actual respiratory rate and core temperature, as well as careful interpretation of chest radiographs, are required. This caution is especially true in the elderly. The clinical diagnosis of community-acquired pneumonia is made based on respiratory symptoms such as cough, sputum production, dyspnea, chest pain, signs of fever, and hypoxemia, as well as an infiltrate on chest imaging.

The diagnosis of CAP is sometimes difficult because viruses, fungi, and mycobacteria may cause pneumonia, although the main causative pathogens are bacteria. In addition, there are many non-infectious diseases in the differential diagnosis of CAP, such as pulmonary edema, lung cancer, acute respiratory distress syndrome, and many interstitial lung diseases.

Continued in the report…..

Community-Acquired Bacterial Pneumonia Epidemiology Perspective by DelveInsight

Community-acquired pneumonia is a leading cause of hospitalization, and mortality, and incurs significant healthcare costs. The disease presentation varies from a mild illness that can be managed as an outpatient to a severe illness requiring treatment in the intensive care unit. It is a growing health concern, with increasing incidents and antibiotic resistance to the current treatment noted in developed and developing countries.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by incident cases of community-acquired bacterial pneumonia, incidence of community-acquired bacterial pneumonia based on gender, incidence of community-acquired bacterial pneumonia based on severity, incidence of community-acquired bacterial pneumonia based on pathogens, and incidence of community-acquired bacterial pneumonia based on age, in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034.

Community-Acquired Bacterial Pneumonia Detailed Epidemiology Segmentation

• The incidence of community-acquired bacterial pneumonia is projected to increase in the next decade due to the aging population and subsequent increase in susceptibility to comorbidities. The total incident population of community-acquired bacterial pneumonia associated was estimated to be around 6.9 million in 2023, in the 7MM.
• Of the total incident cases of community-acquired bacterial pneumonia in the 7MM, approximately 54% were found to be in the US, while EU4 and the UK accounted for 31% of the total cases, and Japan for nearly 14% of the total cases, which is projected to increase with an increase in antibiotic-resistance globally.
• The disease has a higher preponderance in males than in females and has a higher risk of worse outcomes in men than women. In 2023, there were around 57% of males and 43% of females with community-acquired bacterial pneumonia, in the US.
• The severity of community-acquired bacterial pneumonia can vary widely, ranging from mild cases characterized by fever, cough, and shortness of breath to severe cases requiring hospitalization. In EU4 and the UK, mild forms of disease accounted for the majority of community-acquired bacterial pneumonia cases, with nearly 64%, followed by moderate with 30%, and severe with 6%, in 2023. The severity of community-acquired bacterial pneumonia is a significant concern due to its association with high mortality rates and substantial morbidity.
• The incidence of community-acquired bacterial pneumonia varies based on the pathogen causing the infection. According to DelveInsight estimates, Streptococcus pneumonia is the most common cause of community-acquired bacterial pneumonia, accounting for 37% of the cases in the US, and 68% of the cases in EU4 and the UK. Other pathogens, such as Pseudomonas aeruginosa, Haemophilus influenzae, and Staphylococcus aureus, are also significant contributors. In Japan, Haemophilus influenzae, and Staphylococcus aureus accounted for around 19% and 18% of the total cases, in 2023. 
• Age is an important risk factor for the increase in community-acquired bacterial pneumonia cases. The aging population is more susceptible to pneumonia due to weakened immune systems and underlying health conditions such as chronic lung disease, heart disease, liver cirrhosis, or diabetes. In the US, there were approximately 259 thousand, 331 thousand, 260 thousand, and 154 thousand cases of community-acquired bacterial pneumonia, for the age groups 18-49, 50-64, 65-79, and 80 and above in 2023. 
• To address the increasing cases of community-acquired bacterial pneumonia, healthcare professionals emphasize the importance of early diagnosis and appropriate antibiotic stewardship. 

Scope of the Report

• The report covers a descriptive overview of community-acquired bacterial pneumonia, explaining its signs and symptoms, causes, and classification.
• The report provides insight into the 7MM historical and forecasted patient population covering the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• The report assesses the disease risk and burden of community-acquired bacterial pneumonia.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM, incident cases of community-acquired bacterial pneumonia, incidence of community-acquired bacterial pneumonia based on gender, incidence of community-acquired bacterial pneumonia based on severity, incidence of community-acquired bacterial pneumonia based on pathogens, and incidence of community-acquired bacterial pneumonia based on age.

Report Highlights

• 10-year forecast of Community-Acquired Bacterial Pneumonia
• The 7MM Coverage
• Incident Cases of Community-Acquired Bacterial Pneumonia 
• Incidence of Community-Acquired Bacterial Pneumonia Based on Gender
• Incidence of Community-Acquired Bacterial Pneumonia Based on Severity
• Incidence of Community-Acquired Bacterial Pneumonia Based on Pathogens
• Incidence of Community-Acquired Bacterial Pneumonia Based on Age

Key Questions Answered

• What are the disease risks and burdens of community-acquired bacterial pneumonia?
• What is the historical community-acquired bacterial pneumonia patient population in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• What would be the forecasted patient population of community-acquired bacterial pneumonia at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population of community-acquired bacterial pneumonia?
• Out of the above-mentioned countries, which country would have the highest incident population of community-acquired bacterial pneumonia during the forecast period (2024–2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2024–2034)?

Reasons to buy

The Community-Acquired Bacterial Pneumonia report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM community-acquired bacterial pneumonia epidemiology forecast.
• The community-acquired bacterial pneumonia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The community-acquired bacterial pneumonia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Risk of disease by the segmentation 
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034